ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Ardelyx, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about its product XPHOZAH and its revenue potential [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Ardelyx securities between October 31, 2023, and July 1, 2024 [1]. - The Schall Law Firm is representing the investors and encourages those who suffered losses to contact them before October 15, 2024 [1]. - The class has not yet been certified, meaning potential class members are not yet represented by an attorney [2]. Group 2: Allegations Against Ardelyx - The complaint alleges that Ardelyx made false and misleading statements regarding its XPHOZAH phosphorus inhibitor and its inclusion in the Transitional Drug Add-on Payment Adjustment program (TDAPA) [2]. - Ardelyx claimed it was pursuing inclusion of XPHOZAH in the TDAPA, but had not made a firm decision on the application [2].